Asia
Pharma and biotech companies from across the globe provide business and pipeline updates, with news from Gecko, ValGenesis, NeuClone, Zymeworks, and more.
The panel opposed approval of Daiichi Sankyo’s AML drug but supported approval for its TGCT treatment.
Teijin Limited announced today that it has signed a research and development agreement with the Japan Agency for Medical Research and Development (AMED) to form an industry-government-academia partnership that will explore preventive and therapeutic drugs for frail elderly people as designated under AMED’s Cyclic Innovation for Clinical Empowerment program(CiCLE) in October 2018.
Researchers with the RIKEN Center for Brain Science and Ochanomizu University evaluated a treatment for stroke that appears to decrease the damage to the brain. The scientists studied the approach in mice.
Eisai Co., Ltd. announced today that it has entered into a license agreement with medac Gesellschaft fur klinische Spezialpraparate mbH for the commercialization of its anti-rheumatic agent methotrexate (MTX) subcutaneous injection (pre-filled syringe) in Japan.
For Upcoming Clinical Studies on Prevention of Alzheimer’s Disease
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
An ageing global population and a general increase in health awareness are boosting demand for medical and healthcare equipment.
Eisai Co., Ltd. and Allm Inc. have entered into a capital and business alliance agreement for ICT digital health solutions in various areas as well as regional medical treatment and care.
Eisai Co., Ltd. announced that the company has commenced a venture investment business for the purpose of excavating innovative technologies, supporting venture businesses with such technologies, and partnering with those businesses in the future, so as to accelerate innovation in drug creation as well as the establishment of ecosystem platform.
PRESS RELEASES
